The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
November 2020
in “
Frontiers in immunology
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → 
Studysummary This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The IL-23/IL-17 pathway played a crucial role in the pathogenesis of various inflammatory skin diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. IL-17, primarily secreted by Th17 cells, was stimulated by IL-23. Clinical trials demonstrated that monoclonal antibodies targeting IL-23, IL-17, and tumor necrosis factor were effective treatments for these conditions. The document summarized the biology, signaling, and pathophysiological functions of the IL-23/IL-17 axis and discussed the available biologics targeting this pathway.
